Cyclo Therapeutics, Inc.
CYTHDelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000922247
Cyclo Therapeutics, Inc. was delisted in 2025; its insiders filed their last Form 4 on Mar 3, 2025; 22 institutions reported holding it in 13F filings for Q4 2024, worth $1.33M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 22
- Q4 2024, +3 vs. previous quarter
- 13F value
- $1.33M
- Reported value at the end of Q4 2024
- Superinvestors holding
- 0
- At the end of Q4 2024
Superinvestors holding CYTH, Q4 2024
No superinvestor reported holding CYTH at the end of Q4 2024.
Latest insider trades
Open-market purchases and sales by Cyclo Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 23, 2023 (view filing)6:08 AM ET | Oct 20 | 3 days | Rafael Holdings, Inc.10% Owner | PPurchase | +2.77M | – | – | –2.77M after | Derivative |
| Oct 23, 2023 (view filing)6:07 AM ET | Oct 20 | 3 days | Ostronic Francis PatrickDirector | PPurchase | +65.9K | – | – | –65.9K after | Derivative |
| Oct 23, 2023 (view filing)6:06 AM ET | Oct 20 | 3 days | Sieger MarkusDirector | PPurchase | +65.9K | – | – | –65.9K after | Derivative |
| Oct 23, 2023 (view filing)6:06 AM ET | Oct 20 | 3 days | Tate JeffreyChief Operating Officer | PPurchase | +32.9K | – | – | –32.9K after | Derivative |
| Oct 23, 2023 (view filing)6:05 AM ET | Oct 20 | 3 days | Fine N ScottChief Executive Officer | PPurchase | +329.3K | – | – | –329.3K after | Derivative |
| Aug 2, 2023 (view filing) | Aug 1 | 1 day | Rafael Holdings, Inc.10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +4.00M | $1.25 | +$5.00M | +159.0%6.51M after | |
| Aug 2, 2023 (view filing) | Aug 1 | 1 day | Rafael Holdings, Inc.10% Owner | PPurchase | +4.00M | $0.00 | $0 | –4.00M after | Derivative |
| Apr 24, 2023 (view filing)11:00 AM ET | Apr 20 | 4 days | Tate JeffreyChief Operating Officer | PPurchase | +29.9K | $0.71 | +$21.3K | +93.1%62.1K after | |
| Apr 24, 2023 (view filing)11:00 AM ET | Apr 20 | 4 days | Tate JeffreyChief Operating Officer | PPurchase | +29.9K | $0.125 | +$3.74K | –29.9K after | Derivative |
| Apr 24, 2023 (view filing)10:28 AM ET | Apr 20 | 4 days | Fine N ScottChief Executive Officer | PPurchase | +299.4K | $0.71 | +$212.6K | +206.5%444.4K after |
Top 10 13F holders, Q4 2024
The largest institutional positions in Cyclo Therapeutics, Inc. at the end of Q4 2024; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| EPIQ Capital Group, LLC | 689,447 | $406.8K | 0.11% | −49,979−6.8% | Reduced |
| Vanguard Group Inc | 598,694 | $353.2K | 0.00% | 00.0% | Unchanged |
| Founders Fund V Management, LLC | 480,708 | $283.6K | 16.84% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 152,332 | $89.9K | 0.00% | 00.0% | Unchanged |
| Founders Fund VI Management, LLC | 110,023 | $64.9K | 100.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 83,822 | $49.5K | 0.00% | +301+0.4% | Added |
| Two Sigma Securities, LLC | 42,541 | $25.1K | 0.00% | +42,541 | New |
| State Street Corp | 39,530 | $23.3K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 21,736 | $12.8K | 0.00% | +14+0.1% | Added |
| Wealth Enhancement Advisory Services, LLC | 18,285 | $10.8K | 0.00% | −5,115−21.9% | Reduced |